Immunic (NASDAQ:IMUX) Raised to “Hold” at StockNews.com

Immunic (NASDAQ:IMUX) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

A number of other research analysts have also recently issued reports on the company. D. Boral Capital reissued a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Friday, February 21st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Trading Down 3.4 %

Shares of IMUX opened at $1.12 on Wednesday. The stock has a 50 day simple moving average of $1.06 and a 200-day simple moving average of $1.23. The stock has a market cap of $100.89 million, a PE ratio of -0.91 and a beta of 1.89. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11.

Institutional Investors Weigh In On Immunic

A number of hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC raised its stake in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the last quarter. HB Wealth Management LLC acquired a new stake in shares of Immunic in the fourth quarter valued at approximately $81,000. State Street Corp raised its position in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at $50,000. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.